Table 5 Review of literature since 2000: WAI and/or chemotherapy in patients with advanced endometrial cancer
Authors (year) | No. patients | Treatment | Design | Outcomes | Comments | Median follow-up |
|---|---|---|---|---|---|---|
Smith RS [6] | 48 | WAI only | retrospective | 60% 3-y FS (79% for EAC and 47% for PS/CC) | EAC: stage III-IV | 37 mo. |
77% 3-y OS (89% for EAC and 68% PS/CC) | PS/CC: stage I-IV | |||||
Stewart KD [7] | 119 | WAI only | prospective | Stage III 5-y OS: 67% for EAC and 40% for SP/CC | Stage III n = 81 (68%) | 5.8 y |
Stage III 5-y DFS: 62% for EAC and 34% for SP/CC | ||||||
Dusenbery KE [9] | 86 | WAI only | retrospective | 55% 5-y PFS, 46% 10-y PFS, 38% 20-y PFS | Concurrent cisplatin in 13/86 | 10 y |
57% 5-y OS, 48% 10-y OS, 41% 20-y OS | ||||||
Sutton G [8] | 34 | WAI only | prospective | 38% 5-y PFS for PS | Stage I/II PS and CC only | unknown |
54% 5-y PFS for CC | ||||||
Randall ME [5] | 422 | Chemo vs. WAI | prospective | 5-y PFS: 50% for chemo and 38% for WAI | Adjusted for stage | 74 mo. |
5-y OS: 55% for chemo and 42% for WAI | ||||||
Alvarez Secord A [11] | 356 | Chemo vs. RT vs. multi-modality | retrospective | 3-y PFS: 19% (chemo), 59% (RT), 62% (MM) | 39% of WAI in RT group | 38 mo. |
3-y OS: 33% (chemo), 70% (RT), 79% (MM) | ||||||
Fowler JM [20] | 31 | Multi-modality: chemo + WAI | prospective | 53% 5-y PFS | Chemo 3 × AC | 21 mo. |
60% 5-y OS | ||||||
Rochet N (present study) | 20 | Multi-modality: chemo + WAI | retrospective | 63% 1-y, 57% 2- and 3-y RFS | TP based chemo | 31.2 mo. |
83% 1-y, 70% 2-y, 62% 3-y, 53% 4-and 5-y OS | ||||||
Secord A [14] | 109 | Multi-modality: “sandwich” CRC vs. RC vs. CR | retrospective | 3-y PFS: 69% (CRC), 47% (RC), 52% (CR) | various chemo (79% TP) | 2.8 y |
3-y OS: 88% (CRC), 54% (RC), 57% (CR) | ||||||
WAI in 13% | ||||||
Bruzzone M [12] | 45 | Multi-modality: chemo + pelvic RT | retrospective | 30% 9-yPFS | 4 × PAC | 63 mo. |
53% 9-y OS | No WAI | |||||
Geller MA [13] | 42 | Multi-modality: “sandwich” chemo + pelvic +/− EFRT | prospective | 87% 1-y PFS, 71% 3-y PFS, 64% 5-y PFS | 6 × TP | 28 mo. |
No WAI | ||||||
95% 1-y OS, 90% 3-y OS, 71% 5-y OS |